ecancermedicalscience

Review

Clinical significance of microRNA-200 and let-7 families expression assessment in patients with ovarian cancer

14 Jun 2021
Severyn Ferneza, Markiyan Fetsych, Roman Shuliak, Halyna Makukh, Natalia Volodko, Roman Yarema, Tara Fetsych

Ovarian cancer (OC) represents the most lethal malignancy in gynaecologic oncology practice and shows a high recurrence rate due to its early chemoresistance to first-line chemotherapy. Yet, timely selection of the correct treatment strategy is likely to prolong a patient’s survival. MicroRNAs (miRNAs) are a class of short non-coding RNAs responsible for the expression of 30%–60% of human genes. In numerous studies, miRNAs have been used to provide the overall prognosis for patients and analyse the process’s prevalence and responses to chemotherapy. In particular, miRNAs as markers for predicting the sensitivity of OC to platinum- and taxane-based chemotherapeutics can significantly improve the treatment efficacy. This article highlights two families of miRNAs: miR-200 and let-7, which are promising for further research on OC and its chemosensitivity.

Related Articles

Goutam Santosh Panda, Vanita Noronha, Subhash Yadav, Amit Joshi, Vijay Patil, Nandini Menon, Rajiv Kumar, Amit Janu, Abhishek Mahajan, Nilendu Purandare, Jai Prakash Agarwal, George Karimundackal, Kumar Prabhash
Marina Vieira Rodrigues de Queiroz, Ana Carolina Tardin Rodrigues de Medeiros, Sarah Pires Toledo, Karina Demoner de Abreu Sarmenghi, Vitor Fiorin de Vasconcellos
Goutam Santosh Panda, Vanita Noronha, Darshit Shah, George John, Anuradha Chougule, Vijay Patil, Rajiv Kumar, Nandini Menon, Ajay Singh, Pratik Chandrani, Abhishek Mahajan, Kumar Prabhash